GlassScriptPhysician profile
Harmenjit Singh Brar
NPI 1245842541
$4,714.58
in general payments reported to CMS, 2019-2025
28 companies · $2,866 in 2025
The $2,866 reported for 2025 was more than what 86% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $383 · 2022: $280 · 2023: $678 · 2024: $507 · 2025: $2,866.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,052.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,051.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Procept Biorobotics Corporation | $948.10 | 2024-2025 | Aquabeam System |
| Dendreon Pharmaceuticals LLC | $901.20 | 2025 | Provenge |
| Boston Scientific Corporation | $323.38 | 2021-2025 | Lithovue, Spaceoar Vue System - 10ml, Ams 700 |
| Olympus America INC. | $255.58 | 2023-2025 | Itind System, Soltive, Bovie |
| Sumitomo Pharma America, INC. | $249.43 | 2024-2025 | Orgovyx, Gemtesa |
| Janssen Biotech, INC. | $244.28 | 2023-2025 | Carvykti, Rybrevant, Erleada |
| Myriad Genetic Laboratories, INC. | $164.28 | 2023 | Prolaris, Myrisk |
| Karl Storz Endoscopy-America | $162.58 | 2021 | |
| Biotissue Holdings INC. | $158.84 | 2022-2023 | |
| Urogen Pharma, INC. | $158.75 | 2022-2025 | |
| Coloplast Corp | $151.38 | 2023 | Titan, Speedicath |
| Cook Medical LLC | $136.85 | 2021-2022 | |
| Uronova Pharmaceuticals, INC. | $120.44 | 2025 | Vabrinty |
| Axonics, INC. | $115.25 | 2024 | Axonics |
| Ferring Pharmaceuticals INC. | $95.50 | 2025 | Adstiladrin |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo USA, INC. | $78.04 | 2025 | Xiaflex |
| Tolmar, INC. | $63.16 | 2023-2025 | Jatenzo, Eligard |
| Immunitybio, INC. | $58.62 | 2025 | |
| Astellas Pharma US INC | $48.58 | 2023-2025 | Myrbetriq, Xtandi |
| C. R. Bard, INC. & Subsidiaries | $46.74 | 2022 | |
| Accord Healthcare, INC. | $41.79 | 2025 | |
| Verity Pharmaceuticals INC. | $41.13 | 2025 | Trelstar |
| Bayer Healthcare Pharmaceuticals INC. | $36.56 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $33.60 | 2022-2023 | Seglentis |
| Medtronic, INC. | $30.44 | 2023 | Interstim |
| Teleflex LLC | $22.18 | 2025 | Urolift |
| Ambu INC. | $14.54 | 2024 | |
| Laborie Medical Technologies Corp. | $13.36 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harmenjit Brar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.